Drug intelligence / Profile preview

LR20011

Development stage: Phase 2
Lead developer: LG Chem
Modality: Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics
Administration: Oral

Overview

LR20011 (also known as GEN-001) is an orally administered live biotherapeutic product (LBP) consisting of a specific strain of *Lactococcus lactis*. Developed by AVEO Oncology (an LG Chem company) in partnership with Genome & Co, LR20011 is designed to modulate the gut microbiome to enhance the host's immune response against solid tumors. The mechanism of action involves the stimulation of immune cells, such as dendritic cells and T cells, and the induction of pro-inflammatory cytokines like IL-12 and IFN-gamma, thereby potentially overcoming resistance to immune checkpoint inhibitors. It is currently being evaluated in clinical trials for various solid tumors, including gastric cancer and biliary tract cancer, typically in combination with PD-1/PD-L1 inhibitors like avelumab or pembrolizumab.

Other names: Lactococcus lactis strain GEN-001

Beyond the preview

Go deeper on LR20011.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LR20011.

Explore the full profile